The management of polycystic liver disease by tolvaptan
Tsuneo Takenaka, Soichiro Miura, Masaki Kitajima
Clin Mol Hepatol. 2020;26(1):70-73.   Published online 2019 Jun 13     DOI: https://doi.org/10.3350/cmh.2019.0026
Citations to this article as recorded by Crossref logo
Polycystic Liver Disease: Advances in Understanding and Treatment
Tatyana V. Masyuk, Anatoliy I. Masyuk, Nicholas F. LaRusso
Annual Review of Pathology: Mechanisms of Disease.2022; 17(1): 251.     CrossRef
Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
Hiroki Mizuno, Akinari Sekine, Tatsuya Suwabe, Daisuke Ikuma, Masayuki Yamanouchi, Eiko Hasegawa, Naoki Sawa, Yoshifumi Ubara, Junichi Hoshino, Tatsuo Shimosawa
PLOS ONE.2022; 17(2): e0264065.     CrossRef
Evidence of nonsurgical treatment for polycystic liver disease
Jeong-Ju Yoo, Hye In Jo, Eun-Ae Jung, Jae Seung Lee, Sang Gyune Kim, Young Seok Kim, Beom Kyung Kim
Therapeutic Advances in Chronic Disease.2022; 13: 204062232211125.     CrossRef
Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment
Luiz Fernando Norcia, Erika Mayumi Watanabe, Pedro Tadao Hamamoto Filho, Claudia Nishida Hasimoto, Leonardo Pelafsky, Walmar Kerche de Oliveira, Ligia Yukie Sassaki
Hepatic Medicine: Evidence and Research.2022; Volume 14: 135.     CrossRef
Klotho supplementation ameliorates blood pressure and renal function in DBA/2-pcy mice, a model of polycystic kidney disease
Tsuneo Takenaka, Hiroyuki Kobori, Tsutomu Inoue, Takashi Miyazaki, Hiromichi Suzuki, Akira Nishiyama, Naohito Ishii, Matsuhiko Hayashi
American Journal of Physiology-Renal Physiology.2020; 318(3): F557.     CrossRef
Management of portal hypertension and ascites in polycystic liver disease
Lucas H. P. Bernts, Joost P. H. Drenth, Eric T. T. L. Tjwa
Liver International.2019; 39(11): 2024.     CrossRef